{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:40:26Z","timestamp":1792726826824,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848017003"],"award-info":[{"award-number":["848017003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cmi.2026.05.019","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T23:37:45Z","timestamp":1779493065000},"page":"1833-1838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining the unbound target exposure of teicoplanin, Part 1: Insights from the hollow-fibre system"],"prefix":"10.1016","volume":"32","author":[{"given":"Jaap W.A.","family":"Mouton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelmer","family":"Raaijmakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian T.","family":"Tandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke G.L.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G. Coen","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.05.019_bib1","first-page":"CD007022","article-title":"Teicoplanin versus vancomycin for proven or suspected infection","volume":"16","author":"Cavalcanti","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.cmi.2026.05.019_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.05.019_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40262-025-01483-7","article-title":"Pharmacokinetics and target attainment of teicoplanin: A systematic review","volume":"64","author":"Mouton","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2026.05.019_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jgar.2020.11.014","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model","volume":"24","author":"Watanabe","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.05.019_bib5","series-title":"Summary of product characteristics for Targocid\u00ae","year":"2016"},{"key":"10.1016\/j.cmi.2026.05.019_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijantimicag.2014.01.023","article-title":"Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study","volume":"43","author":"Roberts","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.05.019_bib7","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/jac\/dkx289","article-title":"Pharmacodynamics of teicoplanin against MRSA","volume":"72","author":"Ramos-Mart\u00edn","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.05.019_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10156-010-0105-1","article-title":"An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication","volume":"17","author":"Kanazawa","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.cmi.2026.05.019_bib9","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/jac\/dkab160","article-title":"Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting","volume":"76","author":"Sadouki","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.cmi.2026.05.019_bib10","series-title":"ISO 20776-1:2019 Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices","year":"2019"},{"key":"10.1016\/j.cmi.2026.05.019_bib11","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.cmi.2026.05.020","article-title":"Defining the unbound target exposure of teicoplanin part 2: Dose individualization through population pharmacokinetic modelling","volume":"32","author":"Mouton","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.05.019_bib12","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1093\/jac\/dkad290","article-title":"Development and validation of a bioanalytical assay for the measurement of total and unbound teicoplanin in human serum","volume":"78","author":"Mouton","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.05.019_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","article-title":"Handling data below the limit of quantification in mixed effect models","volume":"11","author":"Bergstrand","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.cmi.2026.05.019_bib14","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/. Accessed 14 April 2026."},{"key":"10.1016\/j.cmi.2026.05.019_bib15","unstructured":"Fidler M. nlmixr2: Nonlinear mixed effects models in population PK\/PD. R package version 3.0.1; 2025. https:\/\/CRAN.R-project.org\/package=nlmixr2. Last updated: 28 October 2024. Accessed 14 April 2026."},{"key":"10.1016\/j.cmi.2026.05.019_bib16","unstructured":"Fidler M, Hallow M, Wilkins J, Wang W. rxode2: Facilities for simulating from ODE-based models. R package version 2.1.3; 2024. https:\/\/CRAN.R-project.org\/package=rxode2. Last updated: 28 May 2024. Accessed 14 April 2026."},{"key":"10.1016\/j.cmi.2026.05.019_bib17","first-page":"15","article-title":"Pharmacokinetic\/pharmacodynamic analysis of teicoplanin in patients with MRSA infections","volume":"8","author":"Matsumoto","year":"2016","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.cmi.2026.05.019_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijantimicag.2014.11.011","article-title":"Inefficacy of vancomycin and teicoplanin in eradicating and killing Staphylococcus epidermidis biofilms in vitro","volume":"45","author":"Claessens","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.05.019_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s100960000299","article-title":"Glycopeptide resistance in coagulase-negative staphylococci","volume":"19","author":"Biavasco","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26002612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26002612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:22:46Z","timestamp":1792725766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26002612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1198743X26002612"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.019","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining the unbound target exposure of teicoplanin, Part 1: Insights from the hollow-fibre system","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.020","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.06.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}